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Abstract
Alzheimer’s Disease (AD) is the leading cause of dementia in the elderly. In healthy individuals, amyloid precursor protein (APP) is
cleaved by a-secretase, generating soluble a-amyloid precursor protein (sAPPa), which contributes neuroprotective functions in
the neuronal environment. In contrast, in the neurodegenerative environment of AD patients, amyloid-b-peptide (Ab) of either
40 or 42 residues are generated by increased activity of b- and g-secretase. These proteins amalgamate in specific regions of the
brain, which disrupts neuronal functions and leads to cognitive impairment. Human umbilical cord blood cells (HUCBC) have
proven useful as potential immunomodulatory therapies in various models of neurodegenerative diseases, including AD. Our
most recent work studied the impact of umbilical cord blood serum (CBS) on modulation of sAPPa production. Heat-sensitive
CBS significantly promoted sAPPa production, indicating that heat-sensitive factor(s) play(s) a role in this process. Liquid
chromatography with tandem mass spectrometry (LC-MS/MS) analysis was used to determine the molecular source of
a-secretase in purified CBS and aged blood serum (AgBS) fraction. Of the proteins identified, the subunits of C1 complex
(C1q, C1r, and C1s) and alpha-2-macroglobulin showed significantly greater levels in purified a-CBS fraction (a-CBSF) compared
with the AgBS fraction (AgBSF). Specifically, C1 markedly increased sAPPa and alpha-carboxyl-terminal fragment (a-CTF)
production in a dose-dependent fashion, whereas C1q alone only minimally increased and C3 did not increase sAPPa
production in the absence of sera. Furthermore, C1q markedly increased sAPPa and a-CTF, while decreasing Ab, in CHO/
APPwt cells cultured in the presence of whole sera. These results confirm our initial assumption that APP a-secretase activity
in human blood serum is mediated by complement C1, opening a potential therapeutic modality for the future of AD.
Keywords
Alzheimer’s Disease, Ab, complement C1 complex, complement system, cord blood serum, human umbilical cord blood cell,
soluble a-amyloid precursor protein, amyloid precursor protein
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Introduction
Alzheimer’s Disease (AD) is the most common neurodegenerative disorder, characterized by the presence of intracellular neurofibrillary tangles, extracellular b-amyloid plaques,
and neuronal loss throughout the entire brain. Ab, a 4 kDa
peptide, is one of the major components of b-amyloid plaques. Under physiological conditions, a-secretase cleaves
APP within the Ab domain, thereby preventing generation
of Ab and releasing soluble neurotrophic sAPPa1. sAPPa
has been shown to reduce Ab generation and plaque deposition by interfering with beta-site APP cleaving enzyme 1
(BACE1), also known as b-secretase2,3. In addition, sAPPa
has also been shown to inhibit tau phosphorylation through
modulation of the GSK3b signaling pathway 4 . In the
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neurodegenerative environment of AD, sequential cleavage
of APP by b- and g-secretases generates Ab peptides, either
40 or 42 residues in length, which aggregate in the brain5.
Eventually, these protein aggregates trigger neuroinflammation and neurodegeneration, ultimately leading to cognitive
impairment and memory dysfunction6. One of the prominent
facets of AD neuropathology is the colocalization of activated inflammatory proteins of the complement pathways
with the disease pathology7.
Human umbilical cord blood cells (HUCBCs) have
emerged as a potential immunomodulatory therapy in various diseases, including ischemia and neurodegeneration8.
The many benefits of HUCBC include attenuation of amyloidogenic APP processing and reduction of Ab levels in
PSAPP and Tg2576 mice models of AD9. Importantly, multiple low-dose HUCBC infusion has also been shown to
improve cognitive functions in transgenic PSAPP mice10.
Our most recent work showed that cord blood serum (CBS)
significantly promoted sAPPa production, whereas heatinactivation eliminated this effect. Furthermore, sAPPa production was found to be increased by the removal of serum
immunoglobulins and salts. To further understand what
exactly in CBS was promoting sAPPa, we isolated the specific fraction of CBS found to have the highest a-secretase
activity (a-CBSF) by a three-step chromatographic process.
The proteolytic a-secretase activity in a-CBSF was found to
not be mediated by tumor necrosis factor-a converting
enzyme (TACE) or a disintegrin and metalloproteinase
domain-containing protein (ADAM)10. Immunoprecipitation studies indicated the presence of an a-secretase-like
enzyme that physically interacts with APP 11 . As first
reported, following the administration of a-CBSF by intracerebroventricular (ICV) injection, both Ab levels and tau
phosphorylation were reduced in 3xTg-AD mice. Amyloid
plaque numbers were decreased in the neocortex and hippocampus of 5XFAD mice through a-CBSF intraperitoneal
minipump administration in comparison with mouse brain
treated with the corresponding AgBSF. Furthermore, ICV
administration of a-CBSF enhanced non-amyloidogenic
APP processing in 3xTg-AD mice, providing a neuroprotective effect. These results combined with reduced neuronal
loss in the neocortex of the 5XFAD mouse model following
a-CBSF administration reveal a therapeutic potential for
improving synaptic plasticity and neuroinflammation11.
The complement system is a major part of the innate
immune system involved in neuroprotection via activation
of immunomodulatory pathways12. In fact, a growing body
of evidence suggests that complement proteins have neuroprotective effects in the developing and adult brain13,14.
Neurogenesis and synapse elimination are heavily influenced by the complement system, particularly in the early
stages of neurodevelopment13,15. Complement protein C1
complex is most commonly known for its neuroprotective
role in enhancing and refining the neural network through
phagocytosis of apoptotic cells and immune complexes16.
The C1 complex is composed of a C1q and two each of
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C1r and C1s molecules. C1q, the largest subcomponent of
the cascade initiator of the C1 pathway, is composed of six
each of A, B, and C chains, comprising 18 polypeptide
chains17. In addition to a role in synaptic elimination, complement protein subcomponent C1q has been shown to
increase neuronal survival and branching in absence of other
complement components, 18 and this effect could be
mediated via upregulation of genes associated with neurotrophic factors (neural growth factor, and neurotrophin 3),
cytoskeletal (syntaxin-3), and cholesterol metabolism (cholesterol-25-hydroxylase)19. During development, C1q is
expressed in synaptic regions, and synapse elimination is
mediated by C1q during the period of synaptic pruning.
Therefore, deficiencies in C1q or downstream complement
components can lead to neuronal defects and other detrimental effects15. These data confirm a direct neuroprotective role
of C1q in the physiological condition. In peripheral phagocytes C1q downregulates pro-inflammatory cytokine expression and supports the overall clearance of cellular debris.
C1q binds to apoptotic cells, flagging them to be cleared out
before they release neurotoxic components20. Despite several physiological functions, dysregulated activation of the
complement pathways in the central nervous system (CNS)
have usually been considered detrimental in various conditions, including AD21. Treatment with a cyclic hexapeptide
C5a receptor antagonist (PMX205) has been shown to
reduce fibrillary amyloid deposition and glial activation,
while rescuing cognitive impairment in a passive avoidance
task in Tg2576 Swedish mutant mice22. Neuronal C1q is
normally downregulated in adult CNS, but is found to be
upregulated in the advent of injury or early stages of
disease13. Interestingly, C1q is found to be induced in the
brain in response to neuronal injuries in AD and blocks
fibrillary forms of Ab neurotoxicity in vitro23. Benoit et al.
demonstrated that C1q protects both immature and mature
primary neurons against fibrillary and oligomeric Ab
toxicity24. Depending on the timing and environment, C1q
can either be neuroprotective or induce an inflammatory
environment, leading to neurodegeneration in the adult
brain. Loeffler et al. reported that C3b and iC3b (i.e., proteolytically inactive product of C3b which prevents
complement cascade activation) are also accumulated on
AD-affected neurons, much like C1q25.
Given that sAPPa has anti-amyloidogenic properties, the
primary known a-secretases that cleave APP are nonspecific,
and stimulating them could generate unwanted off-target
effects. Our preliminary data show that a-secretase-like enzymatic activity in CBS is not mediated by ADAM10 or TACE,
the major a-secretases that cleave APP in AD. In addition, we
purified and identified a CBS-specific fraction a-CBSF, with
more than 1000-fold increased a-secretase activity, which
markedly increased cerebral sAPPa, decreased Ab production and abnormal tau phosphorylation, and ameliorated cognitive impairment in two (3xTg-AD and 5XFAD) AD mouse
models11. In support of this hypothesis, we have tested further for the identification of the heat-sensitive protein
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factor(s) exerting this novel enzymatic function. Here, we
have recently identified a novel role for complement
protein C1 complex in the CNS. Multi-step fractionation
followed by liquid chromatography with tandem mass
spectrometry (LC-MS/MS) analyses of CBS have identified several proteins compared to AgBS, each of which
could potentially generate sAPPa by cleaving APP in the
cellular system. Utilizing in vitro CHO/APPwt, N2a/
APPwt, and TgAPPwt primary neuronal cell lines, we
found that a-secretase-like enzymatic activity promoting
sAPPa may be in part mediated by complement protein C1
complex. These results point to a novel neurotrophic function
of complement protein C1 complex, which requires further
investigation.

Materials and Methods
Reagents and Antibodies
CBS was obtained from Lee Biosolutions (St. Louis, MO,
USA). CBS was separated from umbilical cord blood by allowing clotting for 5–10 h in tubes without anticoagulant followed
by centrifugation at 3500 rpm for 5–10 min and filtration
through a membrane with a pore size of 0.22 mm. Individual
CBS samples were prepared from a single lot of cord blood,
and more than 10 samples of CBS were combined as “pooled
CBS.” Normal human aged blood serum (AgBS, >75 years
old) were obtained from Florida Blood Services (Tampa, FL,
USA). All sera were heat-activated. Heat-inactivation of
human sera was conducted at 56 C for 30 min. Complement
proteins, complement depleted sera, and complement inhibitors were acquired from the following sources. Human complement protein C1 inhibitor (Cat# GF178), complement
protein C1 from human serum (Cat# 204873), complement
protein C3-depleted human serum (Cat# 234403), and complement protein C1q-depleted human sera (Cat# 234401) from
MilliporeSigma (St. Louis, MO, USA). Complement protein
C3 from human serum (Cat# A113) and complement iC3b
from human serum (Cat# A115) from Complement Technology, Inc. (Tyler, Texas, USA). Complement protein C1q from
human serum (Cat# 204876) from MilliporeSigma (St. Louis,
MO, USA). Compstatin, complement protein C3b inhibitor
human (Cat# SB 431542) was acquired from Tocris Bioscience
(Minneapolis, MN, USA). Sera from C1qa deficient (def) mice
(129P2/OlaHsd, 3 months of age) were kindly provided by Dr.
Andrea J. Tenner (University of California, Irvine, USA). Antibodies used in this studies include: specific anti-sAPPa monoclonal antibody (2B3; IBL, Minneapolis, MN, USA, Cat#
11088 RRID: AB_494690), anti-APP C-terminal polyclonal
antibody (pAb751/770; EMD Millipore, La Jolla, CA, USA,
Cat# 171610, RRID: AB_211444), anti-N-terminal Ab monoclonal antibody (6E10; Covance Research Products, Emeryville, CA, USA), and anti-b-actin monoclonal antibody (Cat#
A5316, RRID: AB_476743) from MilliporeSigma (St. Louis,
MO, USA). The human sAPPa ELISA assay kit was purchased
from IBL AMERICA, Minneapolis, MN, USA.

Fig. 1. Tentative workflow for a-CBSF and AgBSF fractionation.
Initially, CBS and AgBS were desalted followed by sequential chromatographic separation using DEAE column, size-exclusion, and
ion-exchange chromatography. Each fraction was collected followed by efficacy testing by treating CHO/APPwt cells for sAPPa
release. Eventually a fraction (a-CBSF) was chosen based on the
highest capacity for sAPPa generation. LC-MS/MS was performed
to identify the source of the protein function. AgBS, aged blood
serum; CBS, cord blood serum; DEAE, diethylaminoethyl; LC-MS/
MS, liquid chromatography with tandem mass spectrometry;
sAPPa, secreted amyloid precursor protein-a.

CBS and AgBS Fractionation
In order to purify and characterize the a-secretase in CBS
or AgBS, the Econo-Pack Serum IgG purification kit, and
10 DG columns (Bio-Rad, Philadelphia, PA, USA) were
initially employed to remove highly abundant IgG and
salts. The desalted serum was applied to DEAE Affi-Gel
blue columns and residual IgG was eluted according to the
instructions. Then, 20 additional protein fractions were collected by eluting with an ionic strength gradient of NaCl
buffer ranging from 0.1 M to 2.0 M. The remaining proteins
on the column were eluted by the regeneration buffer
included in the kit and collected as the regeneration fraction. The 0.8 M NaCl eluted protein fractions were combined and sent to Moffitt Cancer Center protein purification
core for further separation by size-exclusion chromatography, employing analytic Superdex 200 columns and eluting
with phosphate-buffered saline (PBS), and ion-exchange
chromatography, employing Q-Sepharose columns and
eluting with 500 mM NaCl, 50 mM Tris, pH 7.6. The final
enzyme containing fractions were exchanged to PBS buffer
by Ultracel-10 membranes (10 kDa, Merck Millipore, Burlington, MA, USA) for further experimentation and
referred to as a-CBSF or AgBSF (Fig. 1).

LC-MS/MS
Briefly, each lane gel slices were destained using acetonitrile and subjected to tris 2-carboxyethy-phosphine (TCEP)
reduction and iodoacetamide alkylation followed by in-gel
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trypsin digestion, extraction, and vacuum centrifugation
concentration. A nanoflow liquid chromatograph (U3000,
Dionex, Sunnyvale, CA) coupled to an electrospray ion trap
mass spectrometer (LTQ-Orbitrap, Thermo, San Jose, CA)
was used for tandem mass spectrometry peptide sequencing
experiments. A 5 ml sample was first loaded onto a precolumn (5 mm  300 mm ID packed with C18 reversedphase resin, 5 mm, 100 Å) and washed for 8 min with
aqueous 2% acetonitrile and 0.04% trifluoroacetic acid.
Next, the trapped peptides were eluted onto the analytical
column (C18, 75 mm ID  15 cm; Pepmap 100, Dionex,
Sunnyvale, CA). The 120-min gradient was programmed
as: 95% solvent A (2% acetonitrile þ 0.1% formic acid) for
8 min; solvent B (90% acetonitrile þ 0.1% formic acid)
from 5% to 50% in 90 min; then solvent B from 50% to
90% in 7 min and held at 90% for 5 min; followed by
solvent B from 90% to 5% in 1 min and re-equilibrate for
10 min (60-min gradient setup). The flow rate on the analytical column was 300 nl/min. Five tandem mass spectra
were collected in a data-dependent fashion following each
survey scan. The MS scans were performed in Orbitrap to
obtain accurate peptide mass measurement and the MS/MS
scans were performed in a linear ion trap using 60 s exclusion for previously sampled peptide peaks. The LC-MS/MS
data were submitted to a local MASCOT server Swiss-Prot
Human database for MS/MS protein identification search
via ProteomeDiscoverer software. Two trypsin missed
cleavages were allowed; the precursor mass tolerance was
1.08 Da. The MS/MS mass tolerance was 0.8 Da. The
incorrect detection rate in each LC-MS/MS analysis was
set to be less than 1%.

Cell Culture
Chinese hamster ovary (CHO) cell line with stable expression of human wild-type APP (CHO/APPwt) was a generous gift from Drs. Stefanie Hahn and Sascha Weggen
(University of Heinrich Heine, Düsseldorf, Germany).
These cells were initially genotyped to confirm their
genetic make-up. The cells were cultured in Dulbecco’s
modified Eagle’s medium (DMEM) with 10% fetal bovine
serum (FBS), 1 mM sodium pyruvate, and 100 U/ml of
penicillin/streptomycin. For treatment, the cells were plated in a 24-well plate at 2  105 cells/well for overnight
incubation, washed, and treated with CBS, heat-inactivated
(56 C, 30 min) CBS, AgBS, or a-CBSF, AgBSF in DMEM.
After treatment, supernatants were collected and the cells
were washed with ice-cold PBS three times and lysed with
cell lysis buffer (20 mM Tris, pH 7.5, 150 mM NaCl, 1 mM
EDTA, 1 mM EGTA, 1% v/v Triton X-100, 2.5 mM sodium
pyrophosphate, 1 mM b-glycerolphosphate, 1 mM
Na3VO4, 1 mg/ml leupeptin, and 1 mM PMSF; Cell Signaling Technology, Danvers, MA, USA). Both cell supernatants and lysates were used for sAPPa analysis by ELISA.
In addition, murine N2a cells transfected with APPwt (N2a/
APPwt) and primary neuronal cells were obtained from
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cerebral cortices of TgAPPwt mouse embryos, between
15 and 17 days in utero, as described previously26. For
TgAPPwt mouse-derived cortical neurons, cerebral cortices were isolated from TgAPPwt mice between 15 and
17 days in utero and mechanically dissociated in trypsin
(0.25%) individually after incubation for 15 min at 37 C.
Cells were collected after centrifugation at 1200 g, suspended in DMEM supplemented with 10% fetal calf serum,
10% horse serum, uridine (33.6 mg/ml; Sigma-Aldrich, St.
Louis, MO, USA), and fluorodeoxyuridine (13.6 mg/ml,
Sigma-Aldrich), and seeded in 24-well collagen-coated
culture plates at 2.5  105 cells/well. After reaching confluence (*70–80%) these cells were treated with purified
human complement C1 at 0, 5, 10, or 20 mg/ml for 4 h,
supernatants were collected for sAPPa measurement by
ELISA and cells were washed with ice-cold PBS three
times and lysed with cell lysis buffer followed by western
blotting using 6E10 and pAb751/770 antibodies.

Transgenic APPwt Mice
Transgenic wild-type B6.Cg-Tg (PDGFB-APP) 5Lms/J
strain (TgAPPwt) male and female mice were purchased
from the Jackson Laboratory (Bar Harbor, ME, USA). All
mice were housed in the Animal Facility in the College of
Medicine at the University of South Florida and maintained
on a 12 h light/12 h dark cycle at ambient temperature and
humidity with ad libitum access to food and water. All animal experiments involving mice were performed in compliance with the US Department of Health and Human Services
Guide for the Care and Use of Laboratory Animals and in
accordance with the guidelines of the University of South
Florida Institutional Animal Care and Use Committee
(IACUC reference number: IS00000438).

Western Blot Analysis and ELISA
Western blot (WB) analyses and quantification were performed as previously described11. Briefly, the proteins from
the cell-free suspensions, cell lysates, and homogenized tissue were electrophoretically separated using 10% bicine/tris
gel (8 M urea) for proteins less than 5 kDa or 10% tris/SDS
gels for larger proteins. Electrophoresed proteins were transferred to nitrocellulose membranes (Bio-Rad), washed and
blocked for 1 h at room temperature in tris-buffered saline
containing 5% (w/v) nonfat dry milk (TBS/NFDM). After
blocking, membranes were hybridized overnight with various primary antibodies, washed, and incubated for 1 h with
the appropriate HRP-conjugated secondary antibody in TBS/
NFDM and developed using the luminol reagent (Thermo
Fisher Scientific, Waltham, MA, USA). Soluble sAPPa in
the media was quantified with the IBL human sAPPa colorimetric sandwich ELISA kit according to the manufacturer’s
instructions.
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Fig. 2. CBS significantly enhances APP a-cleavage in CHO/APPwt cells. (a) CHO cells overexpressing human wild-type APP (CHO/APPwt
cells) were treated for 0–120 min with CBS (2%). (b) CHO/APPwt cells were treated for 2 h with 0, 0.25, 0.5, 1, 2, and 5% CBS. (c) CHO/
APPwt cells were treated for 2 h with PBS (0% serum, Ctrl), heat-inactivated CBS (Heat CBS), heat-inactivated AgBS (Heat AgBS), AgBS, or
CBS at 2%. (d) CHO/APPwt cells were treated for 2 h with PBS (0% serum, Ctrl), heat-inactivated a-CBSF (Heat aCBSF), heat-inactivated
AgBSF (Heat AgBSF), AgBSF, or a-CBSF at 2%, each purified as briefly described under “Materials and Methods.” Release of sAPPa into the
conditioned medium after treatment was analyzed by ELISA. Data are presented as mean (+SEM) of sAPPa produced (ng/ml or ng/mg) from
three independent experiments performed in triplicate. Significant differences from control treatment are indicated by asterisks (*P < 0.05,
**P < 0.01, ***P < 0.001). AgBSF, aged blood serum fraction; CBS, cord blood serum; PBS, phosphate-buffered saline; sAPPa, secreted
amyloid precursor protein-a; SEM, standard error of the mean.

Statistical Analysis
Comparison between two groups were performed by Student’s t test analysis. For more than two groups, one-way
analysis of variance (ANOVA) followed by least significant
difference (LSD) post hoc analysis was used to compare each
other for statistical significance. Alpha was set at 0.05 for all
analyses. All molecular analyses were repeated three times in
parallel. Data are expressed as mean + SEM. The statistical
package for the social sciences release IBM SPSS 23.0 (IBM,
Armonk, NY, USA) was used for all data analyses.

Results
Heat-Sensitive APP a-Secretase Activity in CBS
In order to identify the source of a-secretase in CBS, we
initially confirmed that CBS possesses heat-labile

a-secretase activity. CHO/APPwt cells were treated with CBS
(2%) for 0, 5, 10, 15, 30, 60, and 120 min, followed by
determination of sAPPa in conditioned medium by ELISA.
CBS caused a time-dependent increase in sAPPa release from
CHO/APPwt cells that was significantly greater than the control treatment (Fig. 2a; *P < 0.05, **P < 0.01, ***P < 0.001).
Similarly, CHO/APPwt cells were treated for 2 h with 0, 0.25,
0.5, 1, 2, and 5% CBS, followed by determination of sAPPa in
conditioned medium by ELISA. CBS caused dose-dependent
release of secreted amyloid precursor protein-a (sAPPa) in
culture medium from CHO/APPwt cells that was significantly
greater than the control treatment (Fig. 2b; *P < 0.05, **P <
0.01, ***P < 0.001). Next, we wanted to determine whether
heat-inactivation of serum reduces the sAPPa-producing
capacity of CBS. CHO/APPwt cells were treated with 2%
whole or heat-inactivated CBS or AgBS (56 C for 30 min)
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showed significantly greater levels in a-CBSF compared
with AgBSF (Fig. 3; *P < 0.05, **P < 0.01). Notably, the
levels of complement proteins C3, C4, C5, C6, and C8 complexes, ApoE, ApoB100, and full-length APP (fAPP) were
not significantly different between a-CBSF and AgBSF (P >
0.05). Complement proteins C1 and C3b complex have proteolytic activity, which can be inactivated at 56 C for 30
min. These proteins play important roles in neurodevelopment and provide early protection against stress or disease,
including AD. Thus, we hypothesized that the heat-labile asecretase activity in CBS is mediated in part by either complement protein C1 complex or C3b.

CBS-Mediated a-Secretase-Like Cleavage of APP is
Independent of Complement C3b

Fig. 3. Identification of proteomic profile of a-CBSF and AgBSF.
The proteome of a-CBSF and AgBSF were analyzed by LC-MS/MS.
From 142 major proteins identified, those exhibiting proteolytic
and therefore potential a-secretase-like activity were selected.
Of these proteins, the subunits of complement protein C1q (**P
< 0.01), C1r (*P < 0.05), and C1s (*P < 0.05), and alpha-2macroglobulin (*P < 0.05) showed significantly greater levels in aCBSF compared with AgBSF. Data are presented as mean (+SEM)
of number of peptide hits from three independent experiments.
Significant difference between AgBSF and a-CBSF indicated by
asterisk (*P < 0.05, **P < 0.001, ***P < 0.01). AgBSF, aged blood
serum fraction; LC-MS/MS, liquid chromatography with tandem
mass spectrometry; SEM, standard error of the mean.

for 2 h followed by determination of sAPPa in conditioned
media by ELISA. Both CBS and AgBS heat-inactivation significantly limited sAPPa-releasing capacity (Fig. 2c; *P <
0.05, **P < 0.01, ***P < 0.001). Furthermore, CHO/APPwt
cells were treated with 2% whole or heat-inactivated a-CBSF
or AgBSF for 2 h followed by determination of sAPPa in
conditioned media by ELISA (Fig. 2d; *P < 0.05, **P <
0.01, ***P < 0.001). As shown most recently, purification
significantly enhanced the sAPPa-producing capacity of CBS
and AgBS, which again was significantly limited by heatinactivation. These results confirm that CBS possesses an
enhanced level of heat-sensitive a-secretase activity.

Proteomic Analyses of CBSF and AgBSF
Having shown that CBSF possesses enhanced a-secretase
activity, we next set out to determine the molecular source
of a-secretase in CBSF and AgBSF by LC-MS/MS analysis.
From 142 major proteins identified, we selected those most
likely to exhibit a-secretase activity. Several of the major
proteins identified in a-CBSF and AgBSF are shown in
Fig. 3. Of these proteins, the subunits of complement protein
C1 complex (C1q, C1r, and C1s) and alpha-2-macroglobulin

In order to determine whether a-secretase activity of CBS is
mediated by activation of complement protein fragment
C3b, we investigated whether depletion of complement protein C3 could limit the a-secretase-like activity of CBS.
CHO/APPwt cells were treated with C3-depleted CBS
(2%) for 0, 15, 30, 60, and 120 min, followed by determination of sAPPa in conditioned medium by ELISA. Depletion
of C3 complement protein did not change sAPPa-producing
capacity of CBS in CHO/APPwt cells (Fig. 4d; *P < 0.05,
**P < 0.01, ***P < 0.001). In order to confirm that C3b
complement does not mediate a-secretase activity in CBS,
we preincubated whole or C3-depleted CBS (2%) with the
C3b inhibitor compstatin at 0, 6, 12, 25, 50, and 100 mM for
15 min at 37 C, and then treated CHO/APPwt cells with
these premix complexes separately for 2 h. Compstatin did
not alter sAPPa production significantly elicited by whole
(Fig. 4a; P > 0.05) or C3-depleted serum (Fig. 4b; P > 0.05).
Therefore, CBS a-secretase-like activity is independent of
enzymatic activity of complement C3b protein.
In order to determine whether complement protein component C3b acts as an inhibitor of CBS a-secretase-like
activity, CHO/APPwt cells were treated for 2 h with premixes of CBS (2%) and iC3b (0, 1.25, 2.5, 5, 10, and 20
mg/ml), the proteolytically inactive product of C3b that prevents complement cascade activation. The sAPPa-producing
capacity of CBS was not altered by iC3b as determined by
sAPPa ELISA (Fig. 4c; P > 0.05), indicating that complement C3b protein does not act as a potent CBS a-secretase
inhibitor.

CBS a-Secretase-Like Activity is Mediated in Part by
Complement Protein C1 Complex
To determine whether a-secretase-like activity in CBS is
mediated by complement protein C1 complex, we determined CBS a-secretase activity in the presence of complement protein C1 inhibitor. CHO/APPwt cells were treated
with a-CBSF (1 and 2%) in the presence of complement
protein C1 inhibitor at 0, 50, 100, and 200 mg/ml for 2 h.
C1 inhibitor markedly reduced sAPPa released by a-CBSF
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Fig. 4. CBS-mediated sAPPa release by CHO/APPwt cells is independent of complement protein C3b. C3b inhibitor compstatin at 0, 6, 12,
25, 50, and 100 mM was preincubated with CBS (2%) as well as C3-depleted CBS (2%) for 15 min. (a). CHO/APPwt cells were treated for 2 h
with CBS (2%) þ compstatin. (b) CHO/APPwt cells were treated for 2 h with C3-depleted CBS (2%) þ compstatin. (c) In addition, CBS (2%)
was preincubated with iC3b at indicated concentrations (0, 1.25, 2.5, 5, 10, and 20 mg/ml). CHO/APPwt cells were treated for 2 h with CBS
þ iC3b. (d). CHO/APPwt cells were treated with C3-depleted CBS (2%) for 0, 15, 30, 60, and 120 min. Release of sAPPa into the
conditioned medium after treatment was analyzed by ELISA. Data are presented as mean (+SEM) of sAPPa produced (ng/mg) from three
independent experiments performed in triplicate. Significant differences from control treatment indicated by asterisk (*P < 0.05, **P < 0.01,
***P < 0.001). CBS, cord blood serum; ELISA, enzyme-linked immunosorbent assay; sAPPa, secreted amyloid precursor protein-a; SEM,
standard error of the mean.

(1 and 2%) in a dose-dependent fashion, as determined by
ELISA (Fig. 5a; *P < 0.05, **P < 0.01, ***P < 0.001) and
WB (2% CBS; Fig. 5b; *P < 0.05, **P < 0.01, ***P < 0.001;
quantification not shown), indicating that a-secretase-like
activity in CBS is mediated in part by complement C1 protein. In addition, we determined the effect of purified human
C1 complement protein on sAPPa production in N2a/APPwt
and TgAPPwt/primary neuronal cells in the absence of sera.
Complement protein C1 dose-dependently increased sAPPa
and a-CTF production in N2a/APPwt cells (Fig. 5c–e; **P <
0.01, ***P < 0.001) and TgAPPwt/primary neuronal cells
(Fig. 5f–h; *P < 0.05, **P < 0.01) in the absence of serum, as
determined by ELISA and WB. These results indicate that
complement protein C1 complex mediates a-secretase-like
activity in CBS.
In order to confirm that complement C1 but not C3 protein has a-secretase-like activity, CHO/APPwt cells were
treated with purified human complement C1 or C3, or C1q
subunit, at 0, 2.5, 5, 10, and 20 mg/ml in serum-free media for
2 h followed by determination of sAPPa in conditioned

medium by ELISA. As expected, complement protein C1
significantly increased sAPPa production in a dosedependent fashion, whereas C1q alone minimally increased
and complement protein C3 did not increase sAPPa production in serum-free medium (Fig. 6a; *P < 0.05, **P < 0.01).
In contrast, both complement C1 and C1q protein component
significantly increased sAPPa production in CHO/APPwt
cells cultured in C1q-depleted sera (Fig. 6b; **P < 0.01,
***P < 0.001), and complement protein C1 significantly
increased sAPPa and a-CTF level, while decreasing Ab and
b-CTF level in CHO/APPwt cells in the presence of whole
sera as determined by WB (Fig. 6c).
In order to investigate the role of complement protein C1
in mediating a-secretase activity in whole blood plasma,
CHO/APPwt cells were treated with plasma from C1qadeficient mice or age-matched wild-type littermates. Interestingly, the production of sAPPa elicited by plasma from
male C1qa-deficient mice was not significantly different
(Fig. 6d; P > 0.05), whereas that elicited by plasma from
female C1qa-deficient mice was significantly greater than
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Fig. 5. A specific complement protein C1 inhibitor significantly reduces APP a-cleavage induced by CBS. (a) CHO/APPwt cells were treated
for 2 h with a-CBSF (1 and 2%) in the presence of C1 inhibitor at 0, 50, 100, and 200 mg/ml, followed by analysis of sAPPa in conditioned
media by ELISA. (b) In addition, CHO/APPwt cells were treated for 2 h with a-CBSF (2%) in the presence of complement protein C1
inhibitor at 0–200 mg/ml, followed by analysis of sAPPa levels by WB. N2a/APPwt cells (c) and TgAPPwt/mouse primary neuronal cells (f)
were treated with purified human complement protein C1 complex at 0, 5, 10, and 20 mg/ml in the serum-free condition for 4 h followed by
analysis of holo APP, sAPPa and a-CTF in cell lysates by WB (c,f). The levels of sAPPa in conditioned media was also determined by ELISA
(d,g) and band density radios of a-CTF to (full-length) holo APP are presented below each blot (e,h). Data presented as mean (+ SEM) of
sAPPa produced (ng/ml or ng/mg) from three independent experiments performed in triplicate. Significant differences from control
treatment indicated by asterisk (*P < 0.05, **P < 0.01, ***P < 0.001). a-CTF, alpha carboxyl-terminal fragment; ELISA, enzyme-linked
immunosorbent assay; sAPPa, secreted amyloid precursor protein-a; SEM, standard error of the mean; WB, western blot.

that elicited by age- and gender-matched plasma from wildtype littermates (Fig. 6d; **P < 0.01). Therefore, plasma
a-secretase activity is not significantly altered by C1qa deficiency in male mice but significantly enhanced by C1qa
deficiency in female mice. These results are consistent with
C1-mediated a-secretase playing an important role in male
and female individuals, but with other a-secretases compensating in its absence. In addition, the elevated sAPPa production capacity in female compared to male C1qa-deficient
mice indicate an unknown function of this neurotrophic fragment in the peripheral system of females.
Altogether, these results confirm that APP a-secretaselike activity in human blood serum is mediated by complement protein C1 complex. The inability of C1q to rescue
a-secretase activity in serum-free media is likely due to the
absence of components C1s and C1r, which are required to
complex with C1q in C1 for proteolytic activity.

Discussion
In our previous study, we have shown that peripheral administration of HUCBC 9 , as well as HUCBC-derived

monocytes27, reduce cognitive impairments and b-amyloid
plaques in PSAPP AD mice. In a subsequent study, we
showed that human CBS also has a-secretase-like activity
that likewise reduces cognitive impairment, tau hyperphosphorylation, and plaque deposition in AD mice11,28. The
present study further investigated the component of CBS that
attenuates b-amyloid plaques, especially through the
increased production of the neurotrophic sAPPa. Our results
confirm the presence of a-secretase-like enzyme activity
within the CBS, reflected by elevated production of sAPPa.
Interestingly, heat-inactivation of a-secretase activity of
CBS at 56  C for 30 min inspired us to assume that
a-secretase-like activity is mediated by a complement protein. This is further reinforced by the result of LC-MS/MS
data, which indicate the dominance of complement protein
C1 subcomponents (C1q, C1r, and C1s), C3b, and C4 proteins in a-CBSF as well as AgBSF (Fig. 3). Further investigations using complement inhibitors and C1 complement
protein-depleted serum reveal that endogenous C1 complex
enhances sAPPa production in cell culture and primary
neuronal cell line, including CHO/APPwt (Fig. 5b), N2a/
APPwt (Fig. 5c–e), and TgAPPwt/primary neuronal cells
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Fig. 6. The purified human complement protein C1 complex promotes APP a-cleavage. (a) CHO/APPwt cells were treated for 2 h with
purified human complement C1q subcomponent, C1 or C3, at 0, 2.5, 5, 10, and 20 mg/ml in serum-free media followed by analysis of sAPPa
in conditioned media by ELISA. (b) CHO/APPwt cells were treated for 2 h with purified human complement C1q subcomponent, C1, and
C3, at 0, 2.5, 5, 10, and 20 mg/ml in C1q-depleted serum followed by analysis of sAPPa in conditioned media by ELISA. (c) In order to further
determine the effect of complement protein C1 on APP processing, CHO/APPwt cells were treated for 2 h with purified complement
protein C1 at 0, 2.5, 5, 10, and 20 mg/ml in the absence of whole serum and cell lysates were prepared from each treated cell culture for
analysis of holo APP, sAPPa, Ab, and a- and b-CTF by WB. (d) CHO/APPwt cells were treated for 2 h with plasma (2%) obtained from C1qadeficient mice or wild-type littermates at 3 months of age (n ¼ 5 males or 3 females for each group) followed by determination of sAPPa in
conditioned media by ELISA. For (a) and (b), data presented as mean (+SEM) of sAPPa produced (ng/ml) from three independent
experiments performed in triplicate. Significant differences from control treatment indicated by asterisk (*P < 0.05, **P < 0.01, ***P < 0.001).
ELISA, enzyme-linked immunosorbent assay; SEM, standard error of the mean; WB, western blot.

(Fig. 5f–h). As previously mentioned, complement protein
C1 is composed of a C1q, and two each of C1r and C1s. C1q
is composed of six each of A, B, and C chains, comprising
18 polypeptide chains 17 . Modifying various factors
revealed that C1q depleted serum elicited less sAPPa production in comparison with the whole serum, highlighting
the crucial nature of C1q-mediated a-secretase activity in
CBS (Fig. 6a–c). Interestingly, our results indicate that the
inability of C1q to rescue a-secretase-like activity in
serum-free media is likely due to the absence of C1s and
C1r subcomponents, which are required to form complexes
with C1q in C1 for proteolytic activity (Fig. 6a). It should
be noted that C1r and C1s are serine proteases that form the
complete initiation complex of C1qC1r2C1s2 when activated by C1q binding to an immune complex29.
Initially, C1q synthesis serves to be protective by aiding
in clearance of apoptotic cells and regulating the environment to prevent further neurotoxicity from spreading23.
It has been proposed that C1q and C3 opsonization30,31
accelerate clearance of Ab. In addition, C1q-mediated
protection against Ab is associated with expression of lowdensity lipoprotein receptor-related protein 1B and Gprotein-coupled receptor 6 as early as 2 months of age in the

3xTg-AD mouse model24. Despite the critical role C1q plays
in immune regulation and neuroprotection, evidence has also
suggested that C1q could potentially be proinflammatory32.
C1q is synthesized when there is an injury in the CNS33. By
binding with b-sheet fibrillary plaques, C1q activates the
complement cascade that can have detrimental inflammatory
consequences via production of the chemotactic factor C5a
and recruitment and activation of microglial cells to the site
of injury. This activation requires association of C1q with
C1r and C1s as in the C1 complex. As the disease pathology
continues to progress, it causes more of the complement
pathways to be activated34. High density of negative charges
in various regions can activate the complement system
through an electrostatic interaction independent of antibodies35. This can be seen with b-amyloid fibrils binding to
arginine-rich segments within the b-chain of C1q36. Consequently, the fragments not only create further inflammation,
attracting glial cells, but can also activate the classical pathway, triggering the release of more pro-inflammatory components. In a study done with APPQ–/– mice, those lacking
C1q were unable to activate the classical pathway because
the fibrillary Ab interaction with C1q is not possible37. In
AD pathology, factors leading to neurodegenerative
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pathways of complement activation include C1q interaction
with not only the b-sheet fibrils, but also hyperphosphorylated tau35. Though these fibrils would normally be cleared
by microglia, binding of C1q to Ab1-42 peptide strands
makes it increasingly difficult for microglia to clear out
neurotoxic debris38. The general trend toward increased
complement activation causes the activated microglia to further exacerbate inflammation as C1q upregulation positively
correlates with the quantity of reactive astrocytes, making
the blood–brain barrier vulnerable28.
Collectively, our results indicate that CBS contains proteins that promote a-secretase-like enzymatic activity (Fig.
2). LC-MS/MS analysis in CBSF and AgBSF revealed the
presence of 142 proteins, of which complement protein C1
subunits and alpha-2-macroglobulin showed significantly
greater levels in a-CBSF compared with AgBSF (Fig. 3).
Upon further study, complement protein C1 subunits showed
enhanced sAPPa production and Ab reduction in cell culture
studies (Figs. 5 and 6). As discussed previously, C1q is
known to have pro-inflammatory and detrimental effects
on neuronal tissue, which will limit the therapeutic application of C1q. There may be other components in a-CBSF
contributing to the beneficial effects observed in transgenic
AD mice. In addition, C1 has a-secretase activity, which
may also compete with the amyloidogenic b-secretase pathway and reduce b-cleavage of APP when a-CBSF is administered in mice. There is much to be learned about the exact
mechanisms of action of C1q, especially how its neurotrophic effects may shift in AD pathology and instead lead
to further acceleration of neuro-detrimental inflammation.
Nevertheless, our research identified an additional and novel
function in CBS by enhancing a-secretase-like activity and
that the overall reduction in b-amyloid plaques incites a
therapeutic potential for attenuating AD pathology.
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